» Articles » PMID: 39000583

Associations Between Diabetes Mellitus and Selected Cancers

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jul 13
PMID 39000583
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is one of the major causes of mortality and is the second leading cause of death. Diabetes mellitus is a serious and growing problem worldwide, and its prevalence continues to grow; it is the 12th leading cause of death. An association between diabetes mellitus and cancer has been suggested for more than 100 years. Diabetes is a common disease diagnosed among patients with cancer, and evidence indicates that approximately 8-18% of patients with cancer have diabetes, with investigations suggesting an association between diabetes and some particular cancers, increasing the risk for developing cancers such as pancreatic, liver, colon, breast, stomach, and a few others. Breast and colorectal cancers have increased from 20% to 30% and there is a 97% increased risk of intrahepatic cholangiocarcinoma or endometrial cancer. On the other hand, a number of cancers and cancer therapies increase the risk of diabetes mellitus. Complications due to diabetes in patients with cancer may influence the choice of cancer therapy. Unfortunately, the mechanisms of the associations between diabetes mellitus and cancer are still unknown. The aim of this review is to summarize the association of diabetes mellitus with selected cancers and update the evidence on the underlying mechanisms of this association.

Citing Articles

Enhancing diabetes therapy with pH-sensitive co-delivery of metformin hydrochloride and glipizide using MCM-48-based dual drug delivery system.

Dasgupta D, Patel A RSC Adv. 2025; 15(9):7191-7199.

PMID: 40052104 PMC: 11883462. DOI: 10.1039/d5ra00204d.


Associations Between Diabetes Mellitus and Neurodegenerative Diseases.

Szablewski L Int J Mol Sci. 2025; 26(2).

PMID: 39859258 PMC: 11765393. DOI: 10.3390/ijms26020542.


Anti-Diabetic Therapies and Cancer: From Bench to Bedside.

Kounatidis D, Vallianou N, Karampela I, Rebelos E, Kouveletsou M, Dalopoulos V Biomolecules. 2024; 14(11).

PMID: 39595655 PMC: 11591849. DOI: 10.3390/biom14111479.

References
1.
Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y . Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003; 9(15):5699-704. View

2.
Remschmidt B, Pau M, Gaessler J, Zemann W, Jakse N, Payer M . Diabetes Mellitus and Oral Cancer: A Retrospective Study from Austria. Anticancer Res. 2022; 42(4):1899-1903. DOI: 10.21873/anticanres.15666. View

3.
Ewald N, Kaufmann C, Raspe A, Kloer H, Bretzel R, Hardt P . Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2011; 28(4):338-42. DOI: 10.1002/dmrr.2260. View

4.
Mellati M, Eaton K, Brooks-Worrell B, Hagopian W, Martins R, Palmer J . Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes. Diabetes Care. 2015; 38(9):e137-8. DOI: 10.2337/dc15-0889. View

5.
Pasello G, Urso L, Conte P, Favaretto A . Effects of sulfonylureas on tumor growth: a review of the literature. Oncologist. 2013; 18(10):1118-25. PMC: 3805154. DOI: 10.1634/theoncologist.2013-0177. View